Short-term outcome of radiofrequency ablation combined with endostar in the treatment of non-small cell lung cancer: A non-randomized controlled trial_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

 LIU Baodong , HU Mu , LIU Lei , QIAN Kun , LI Yuanbo

Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, P.R.China;

Corresponding author：

LIU Baodong, Email: xwliubaodong@aliyun.com

Keywords：

Radiofrequency ablation; recombinant human endostatin (endostar); non-small cell lung cancer

DOI：

10.7507/1007-4848.201708053

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the short-term outcome and safety of radiofrequency ablation (RFA) combined with recombinant human endostatin (endostar) for non-small cell lung cancer (NSCLC) patients. Methods Between December 2013 and December 2014, 80 consecutive patients (50 males, 30 females) with biopsy-proved NSCLC were divided into two groups: a RFA combined treatment group (RFA combined with endostar, 60 patients, 38 males, 22 females, mean age at 67.77±10.43 years) and a RFA alone group (20 patients, 12 males, 8 females, mean age at 67.35±9.82 years). The RFA combined treatment group was divided into three groups according to vascular normalization window of endostar and 20 patients in each group: a combined treatment group 1 (transfusion of endostar after RFA), a combined treatment group 2 (transfusion of endostar for 1 to 3 d before RFA) and a combined treatment group 3 (transfusion of endostar for 4 to 7 d before RFA). The CT scan of the chest was followed up after the treatment, local recurrence and safety was observed. Results There was a statistical difference in local recurrence time among groups (χ² = 11.05, P = 0.011). The effect of the combined treatment group is better than that of the radiofrequency ablation therapy alone group. And in the recombinant human endostatin of tumor vascular normalization time best combination therapy was observed in the near future effect compared with the radiofrequency ablation therapy alone. In this study common complications were associated with radiofrequency ablation. No recombinant human endostatin related complication was found. There was no satistical difference in safety between the combined treatment group and the radiofrequency ablation therapy group (χ²= 0.889, P > 0.05). Conclusion RFA combined with endostar is safe and effective for non-small cell lung cancer.

Citation： LIU Baodong, HU Mu, LIU Lei, QIAN Kun, LI Yuanbo. Short-term outcome of radiofrequency ablation combined with endostar in the treatment of non-small cell lung cancer: A non-randomized controlled trial. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2018, 25(6): 477-481. doi: 10.7507/1007-4848.201708053 Copy

1.	Hiraki T, Gobara H, Mimura H, et al. Percutaneous radiofrequency ablation of clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg, 2011, 142(1): 24-30.
2.	Beland MD, Wasser EJ, Mayo-Smith WW, et al. Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology, 2010, 254(1): 301-307.
3.	Lanuti M, Sharma A, Willers H, et al. Radiofrequency ablation for stage I non-small cell lung cancer: management of locoregional recurrence. Ann Thorac Surg, 2012, 93(3): 921-927.
4.	Steinke K, Haghighi KS, Wulf S, et al. Effect of vessel diameter on the creation of ovine lung radiofrequency lesions in vivo: preliminary results. J Surg Res, 2005, 124(1): 85-91.
5.	Goldberg SN, Gazelle GS, Compton CC, et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. Acad Radiol, 1995, 2(9): 776-784.
6.	刘宝东, 胡牧, 刘磊, 等. 重组人血管内皮抑素在非小细胞肺癌患者肿瘤血管正常化时间窗研究. 中国医学前沿杂志 (电子版), 2017, 9(3): 8-12.
7.	潘杰, 陈绍辉, 卢欣, 等. 全麻下 CT 引导下经皮穿刺射频消融治疗肝内特殊部位的恶性肿瘤. 介入放射学杂志, 2010, 19(6): 478-481.
8.	刘宝东, 支修益. 影像引导下热消融治疗肺部肿瘤的局部疗效评价. 中国医学前沿杂志 (电子版), 2015, 7(2): 11-14.
9.	Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol, 2000, 174(2): 323-331.
10.	Huang G, Chen L. Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin. Cancer Biother Radiopharm, 2009, 24(5): 589-596.
11.	黄桂, 陈龙邦. 重组人内皮抑素对荷人肺腺癌裸鼠肿瘤微环境的调节作用. 癌症进展, 2009, 7(5): 495-499.
12.	Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol, 2010, 136(8): 1201-1211.
13.	Peng F, Xu Z, Wang J, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One, 2012, 7(4): e34646.
14.	Jiang XD, Dai P, Qiao Y, et al. Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer. Clin Transl Oncol, 2012, 14(6): 437-443.
15.	Jiang XD, Dai P, Wu J, et al. Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2012, 83(4): 1272-1277.
16.	Li N, Zheng D, Wei X, et al. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model. J Cancer Res Clin Oncol, 2012, 138(7): 1131-1144.
17.	王泽新, 李艳彦, 朱伟良, 等.恩度联合微波消融治疗鼠肝癌移植瘤研究. 海南医学, 2012, 23(3): 27-29.
18.	温居一, 段蕴铀, 聂青, 等. 氩氦刀冷冻消融序贯重组人血管内皮抑制素治疗晚期复治非小细胞肺癌的临床研究. 武警医学, 2012, 23(2): 120-123.
19.	Ma CH, Jiang R, Li JD, et al. Experimental study of Endostar injection concomitant with cryoablation on lung adenocarcinoma A549 xenografts. Asian Pac J Cancer Prev, 2014, 14(11): 6697-6701.

1. Hiraki T, Gobara H, Mimura H, et al. Percutaneous radiofrequency ablation of clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg, 2011, 142(1): 24-30.
2. Beland MD, Wasser EJ, Mayo-Smith WW, et al. Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology, 2010, 254(1): 301-307.
3. Lanuti M, Sharma A, Willers H, et al. Radiofrequency ablation for stage I non-small cell lung cancer: management of locoregional recurrence. Ann Thorac Surg, 2012, 93(3): 921-927.
4. Steinke K, Haghighi KS, Wulf S, et al. Effect of vessel diameter on the creation of ovine lung radiofrequency lesions in vivo: preliminary results. J Surg Res, 2005, 124(1): 85-91.
5. Goldberg SN, Gazelle GS, Compton CC, et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. Acad Radiol, 1995, 2(9): 776-784.
6. 刘宝东, 胡牧, 刘磊, 等. 重组人血管内皮抑素在非小细胞肺癌患者肿瘤血管正常化时间窗研究. 中国医学前沿杂志 (电子版), 2017, 9(3): 8-12.
7. 潘杰, 陈绍辉, 卢欣, 等. 全麻下 CT 引导下经皮穿刺射频消融治疗肝内特殊部位的恶性肿瘤. 介入放射学杂志, 2010, 19(6): 478-481.
8. 刘宝东, 支修益. 影像引导下热消融治疗肺部肿瘤的局部疗效评价. 中国医学前沿杂志 (电子版), 2015, 7(2): 11-14.
9. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol, 2000, 174(2): 323-331.
10. Huang G, Chen L. Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin. Cancer Biother Radiopharm, 2009, 24(5): 589-596.
11. 黄桂, 陈龙邦. 重组人内皮抑素对荷人肺腺癌裸鼠肿瘤微环境的调节作用. 癌症进展, 2009, 7(5): 495-499.
12. Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol, 2010, 136(8): 1201-1211.
13. Peng F, Xu Z, Wang J, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One, 2012, 7(4): e34646.
14. Jiang XD, Dai P, Qiao Y, et al. Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer. Clin Transl Oncol, 2012, 14(6): 437-443.
15. Jiang XD, Dai P, Wu J, et al. Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2012, 83(4): 1272-1277.
16. Li N, Zheng D, Wei X, et al. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model. J Cancer Res Clin Oncol, 2012, 138(7): 1131-1144.
17. 王泽新, 李艳彦, 朱伟良, 等.恩度联合微波消融治疗鼠肝癌移植瘤研究. 海南医学, 2012, 23(3): 27-29.
18. 温居一, 段蕴铀, 聂青, 等. 氩氦刀冷冻消融序贯重组人血管内皮抑制素治疗晚期复治非小细胞肺癌的临床研究. 武警医学, 2012, 23(2): 120-123.
19. Ma CH, Jiang R, Li JD, et al. Experimental study of Endostar injection concomitant with cryoablation on lung adenocarcinoma A549 xenografts. Asian Pac J Cancer Prev, 2014, 14(11): 6697-6701.

Previous Article
Verification, comparison and melioration of different prediction models for solitary pulmonary nodule
Next Article
Impact of climate change on aortic dissection onset

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Short-term outcome of radiofrequency ablation combined with endostar in the treatment of non-small cell lung cancer: A non-randomized controlled trial

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content